Cellular senescence is a permanent state of cell cycle arrest that occurs in proliferating cells
subjected to different stresses. Senescence is, therefore, a cellular defense mechanism that …

Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …

Abstract The phosphatidylinositol 3-kinase (PI3K)-Akt and the mammalian target of
rapamycin (mTOR) represent two vital intracellular signaling pathways, which are …

PTEN is a potent tumour suppressor, and its loss of function is frequently observed in both
heritable and sporadic cancers. PTEN has phosphatase-dependent and phosphatase …

Phosphatase and Tensin Homolog deleted on Chromosome 10 (PTEN) is a dual
phosphatase with both protein and lipid phosphatase activities. PTEN was first discovered …

Genomic aberrations of the PTEN tumour suppressor gene are among the most common in
prostate cancer. Inactivation of PTEN by deletion or mutation is identified in∼ 20% of …

A patient's response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait,
and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved …

Over the past 20 years, there has been considerable progress in our understanding of the
biological functions of the BRCA1 and BRCA2 cancer susceptibility genes. This has led to …

The development of life-threatening cancer metastases at distant organs requires
disseminated tumour cells' adaptation to, and co-evolution with, the drastically different …

Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via
homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway …